Epigenetic modifications induced by RGC-32 in colon cancer

Experimental and Molecular Pathology

Volumn 88, Issue 1, 2010, Pages 67-76

  Vlaicu, Sonia I ^a   Tegla, Cosmin A ^a   Cudrici, Cornelia D ^a   Fosbrink, Matthew ^a   Nguyen, Vingh ^a   Azimzadeh, Philippe ^a   Rus, Violeta ^a   Chen, Hegang ^a   Mircea, Petru A ^b   Shamsuddin, Abulkalam ^a   Rus, Horea ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acetylation; Colon cancer; Gene array; Histone; Methylation; RGC 32

Indexed keywords

HISTONE H2B; HISTONE H2BK15; HISTONE H2BK18; HISTONE H2BK27; HISTONE H2BK5; HISTONE H2BK8; HISTONE H2BK9; REGULATOR PROTEIN; RGC 32 PROTEIN; SIRTUIN 1; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; NUCLEOTIDE SEQUENCE; TRANSCRIPTION INITIATION;

ACETYLATION; ADENOCARCINOMA; ADENOMA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; IMMUNOENZYME TECHNIQUES; MUSCLE PROTEINS; NERVE TISSUE PROTEINS; PRECANCEROUS CONDITIONS; TISSUE ARRAY ANALYSIS;

EID: 74749091103     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.10.010     Document Type: Article

References (36)

1. Akhurst R.J., and Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J. Pathol. 187 (1999) 82-90
2. Ashburner M., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 (2000) 25-29
3. Attema J.L., et al. Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12371-12376
4. Badea T., et al. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J. Biol. Chem. 277 (2002) 502-508
5. Badea T.C., et al. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J. Biol. Chem. 273 (1998) 26977-26981
6. Bahnassy A.A., et al. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 4 (2004) 22
7. Bondi J., et al. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J. Clin. Pathol. 58 (2005) 509-514
8. Bredel M., et al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J. Clin. Oncol. 24 (2006) 274-287
9. Bukholm I.K., and Nesland J.M. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 436 (2000) 224-228
10. Clarkson D.B., Fan Y., and Joe H. A remark on algoritm 643: FEXACT: An altgoritm for performing Fisher's Exact Test in rxc contingency tables. ACM Trans. Math. Softw. 19 (1993) 484-488
11. Cudrici C., et al. Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis. J. Neuroimmunol. 203 (2008) 94-103
12. Donninger H., et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23 (2004) 8065-8077
13. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8 (2007) 286-298
14. Fang J.Y., et al. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116. Cell Res. 14 (2004) 217-226
15. Firestein R., et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 3 (2008) e2020
16. Fosbrink M., et al. Overexpression of RGC-32 in colon cancer and other tumors. Exp. Mol. Pathol. 78 (2005) 116-122
17. Fosbrink M., et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp. Mol. Pathol. 86 (2009) 87-94
18. Hershko D.D., and Shapira M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 107 (2006) 668-675
19. Huang W.-Y., et al. RGC-32 mediates transforming growth factor-{beta}-induced epithelial-mesenchymal transition in human renal proximal tubular cells. J. Biol. Chem. 284 (2009) 9426-9432
20. Ioachim E.E., et al. Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features. Int. J. Colorectal. Dis. 19 (2004) 325-333
21. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 25 (2006) 435-457
22. Kang Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 (2003) 537-549
23. Manning A.M., et al. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 6 (1991) 1471-1476
24. Massague J. G1 cell-cycle control and cancer. Nature 432 (2004) 298-306
25. Mitani Y., et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J. Pathol. 205 (2005) 65-73
26. Ogino S., et al. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J. Pathol. 210 (2006) 147-154
27. Sagiv E., et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 131 (2006) 630-639
28. Saigusa K., et al. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene 26 (2007) 1110-1121
29. Salh B., et al. Differential cyclin-dependent kinase expression and activation in human colon cancer. Anticancer Res. 19 (1999) 741-748
30. Shen L., and Issa J.P. Epigenetics in colorectal cancer. Curr. Opin. Gastroenterol. 18 (2002) 68-73
31. Takai N., et al. Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol. Cancer Res. 3 (2005) 261-269
32. Tsushima H., et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110 (1996) 375-382
33. Vlaicu S.I., et al. Role of response gene to complement 32 in diseases. Arch. Immunol. Ther. Exp. (Warsz) 56 (2008) 115-122
34. Wotton S., et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 27 (2008) 5856-5866
35. Zhan F., et al. The molecular classification of multiple myeloma. Blood 108 (2006) 2020-2028
36. Zhao P., et al. Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J. Gastroenterol. 12 (2006) 6391-6396